The need for increments up to the maximum dose in the UM/EM populations reflects the finding uncovered by Berard et al. [99], wherein the proportion of pregnant women with depression symptoms was higher in the UM/EM than in the PM CYP2D6 population even when treated with antidepressants. Here, CYP2D6 is linked to depressive disorder.